二甲双胍(MET)联合罗格列酮(RSG)治疗2型糖尿病(T2DM)的临床疗效和安全性研究

Clinical Efficacy and Safety of Metformin (MET) Combined Rosiglitazone (RSG) in the Treatment of Type 2 Diabetes Mellitus (T2DM)

目的：分析二甲双胍（MET）联合罗格列酮（RSG）治疗2型糖尿病（T2DM）的临床疗效和安全性,为临床提供指导。方法：抽取入住某院的88例2型糖尿病患者（2013年6月-2015年12月）作为本次实验的研究对象,对88例2型糖尿病患者实施信封随机分组。对照组44例2型糖尿病患者实施罗格列酮治疗,实验组44例2型糖尿病患者实施二甲双胍联合罗格列酮治疗,分析比较两组2型糖尿病患者的空腹血糖、餐后2h血糖、糖化血红蛋白以及不良反应发生率。结果：对照组2型糖尿病患者的不良反应发生率（20.45%）和实验组患者（25.00%）无显著区别,P〉0.05;但实验组和对照组2型糖尿病患者的空腹血糖、餐后2h血糖、糖化血红蛋白水平存在明显差异,P〈0.05。结论：对2型糖尿病患者采取二甲双胍联合罗格列酮进行治疗,能显著降低患者的空腹血糖、餐后2h血糖、糖化血红蛋白水平,且毒副作用较小。

Objective：To analyze the clinical efficacy and safety of metformin（MET）combined rosiglitazone（RSG）in the treatment of type 2diabetes mellitus（T2DM）,and to provide guidance for clinical treatment.Methods：88patients with type 2diabetes mellitus in a hospital from June 2013 to December 2015 were selected as the subjects and were randomly into two groups.44 cases of patients with type 2diabetes mellitus of control group were given rosiglitazone treatment,and 44 cases of patients with type 2diabetes mellitus of experimental group treated with metformin and rosiglitazone treatment.Then compared the fasting blood glucose,2hpostprandial blood glucose,glycosylated hemoglobin and incidence of adverse reactions of patients with type 2diabetes mellitus of two groups.Results：The incidence of adverse reactions of control group and experimental group was 20.45% and 25.00%respectively,without significant difference,P〉0.05;The fasting blood glucose,2hpostprandial blood glucose,and glycosylated hemoglobin levels of experimental group and control group existed significant difference,P〈0.05.Conclusion：Patients with type 2diabetes mellitus treated with metformin combined rosiglitazone can significantly reduce the fasting blood glucose,2hours postprandial blood glucose,and glycosylated hemoglobin levels,with less toxic side effects.